JAK1 and infection: As well as primary prevention strategies, treatments for managing severe COVID-19 that have been approved by the US Food and Drug Administration include antagonistic antibodies against IL-6R46 and orally available JAK1/2 inhibitors47, raising the prospect of interventions that could reduce the risk of infection-induced metastatic cancer progression.